CorMedix Inc (NASDAQ:CRMD) has earned an average broker rating score of 1.00 (Strong Buy) from the two brokers that cover the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy recommendation.
Brokers have set a 12-month consensus target price of $4.75 for the company and are anticipating that the company will post ($0.08) earnings per share for the current quarter, according to Zacks. Zacks has also given CorMedix an industry rank of 81 out of 255 based on the ratings given to related companies.
Separately, Roth Capital reaffirmed a “buy” rating and set a $6.00 price objective on shares of CorMedix in a research report on Thursday, December 6th.
CRMD traded down $0.04 during trading on Tuesday, reaching $1.64. 11,965 shares of the stock were exchanged, compared to its average volume of 3,030,140. CorMedix has a twelve month low of $0.17 and a twelve month high of $2.74.
CorMedix, Inc, a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its primary focus is on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as dialysis, critical/intensive care, and oncology.
See Also: What is a Swap?
Get a free copy of the Zacks research report on CorMedix (CRMD)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for CorMedix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CorMedix and related companies with MarketBeat.com's FREE daily email newsletter.